Streetbeat News

LGVNR

Longeveron Inc

Employees

26

Industry

Pharmaceutical Preparation Manufacturing

longeveron llc is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. our lead investigational product candidate (lmsc) is based on a specialized cell known as a mesenchymal stem cell that is derived from the bone marrow of healthy young adult donors. our allogeneic, ‘off-the-shelf’ product is under investigation for chronic conditions of the elderly, and other life- threatening diseases, for which no approved therapeutics currently exist: • aging frailty syndrome • alzheimer’s disease • hypoplastic left heart syndrome • the metabolic syndrome

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

During Tuesday's intraday session, several healthcare stocks experienced significant movements. Gainers included Axcella Health (AXLA), Tenon Medical (TNON), Avalo Therapeutics (AVTX), Myomo (MYO), Cosmos Health (COSM), and Comera Life Sciences (CMRA). Losers included Sight Sciences (SGHT), Longeveron Inc. - Subscription Right (LGVNR), Orthofix Medical (OFIX), PAVmed (PAVM), NovaBay Pharmaceuticals (NBY), and Inspire Veterinary (IVP).

Portfolio Pulse from Benzinga Insights

September 12, 2023 | 5:31 pm

Longeveron Inc. (NASDAQ:LGVN, NASDAQ:LGVNR), a clinical stage biotechnology company, announced that an abstract highlighting long-term survival data from its ELPIS 1 trial of Lomecel-B™ for patients with hypoplastic left heart syndrome (HLHS) has been accepted for presentation at the upcoming meeting of the American Heart Association (AHA).

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 12:04 pm

During Wednesday's intraday session, several healthcare stocks experienced significant movements. Gainers included NeuBase Therapeutics (NBSE), Palisade Bio (PALI), Applied Therapeutics (APLT), Cidara Therapeutics (CDTX), Akanda (AKAN), and PAVmed (PAVM). Losers included Longeveron Inc. - Subscription Right (LGVNR), RVL Pharmaceuticals (RVLP), Helius Medical Tech (HSDT), NanoString Technologies (NSTG), Axcella Health (AXLA), and Acer Therapeutics (ACER).

Portfolio Pulse from Benzinga Insights

September 06, 2023 | 5:31 pm

Several healthcare stocks experienced significant movement in Tuesday's after-market session. Akanda, VolitionRX, Virpax Pharmaceuticals, Cue Health, Longeveron Inc. - Subscription Right, and AIM ImmunoTech saw increases, while XBiotech, Carmell Therapeutics, Novo Integrated Sciences, EyePoint Pharmaceuticals, Orgenesis, and Yield10 Bioscience experienced decreases.

Portfolio Pulse from Benzinga Insights

September 05, 2023 | 9:31 pm

In Tuesday's pre-market session, several health care stocks saw significant movement. Helius Medical Tech, Cellectar Biosciences, RVL Pharmaceuticals, Aravive, WAVE Life Sciences, and Rani Therapeutics Hldgs saw increases ranging from 14.21% to 50.5%. Meanwhile, BioCardia, Longeveron Inc. - Subscription Right, Aditxt, electroCore, Axcella Health, and Trxade Health saw declines ranging from 12.05% to 20.4%.

Portfolio Pulse from Benzinga Insights

September 05, 2023 | 1:06 pm

Several healthcare stocks experienced significant price movements during Monday's intraday session. Gainers included Axcella Health, Trxade Health, Novo Integrated Sciences, Longeveron Inc. - Subscription Right, Aspira Womens Health, and Tivic Health Systems. Losers included Biodexa Pharmaceuticals, Catalyst Biosciences, Aditxt, iSpecimen, Inspire Veterinary, and Harpoon Therapeutics.

Portfolio Pulse from Benzinga Insights

September 04, 2023 | 5:31 pm

During Thursday's intraday session, several healthcare stocks experienced significant movements. Acer Therapeutics (ACER), Aditxt (ADTX), NeuBase Therapeutics (NBSE), Longeveron Inc. - Subscription Right (LGVNR), OpGen (OPGN), and Cue Health (HLTH) saw their shares rise, with ACER leading the gainers with a 141.8% increase. On the other hand, Axcella Health (AXLA), OKYO Pharma (OKYO), Aravive (ARAV), Ontrak (OTRK), AEON Biopharma (AEON), and Ontrak (OTRKP) experienced a decline in their stock prices, with AXLA leading the losers with a 30% decrease.

Portfolio Pulse from Benzinga Insights

August 31, 2023 | 5:31 pm

Several healthcare stocks experienced significant movement during Tuesday's intraday session. Notable gainers included Axcella Health (AXLA), Tivic Health Systems (TIVC), Taysha Gene Therapies (TSHA), Akso Health Group (AHG), NeuroPace (NPCE), and P3 Health Partners (PIII). On the other hand, Longeveron Inc. - Subscription Right (LGVNR), T2 Biosystems (TTOO), Pulse Biosciences (PLSE), Capricor Therapeutics (CAPR), Ontrak (OTRKP), and PHAXIAM Therapeutics (PHXM) saw declines.

Portfolio Pulse from Benzinga Insights

August 29, 2023 | 5:31 pm

During Monday's intraday session, several healthcare stocks experienced significant movements. Bionomics (BNOX), XTL Biopharmaceuticals (XTLB), Akebia Therapeutics (AKBA), PHAXIAM Therapeutics (PHXM), Prenetics Global (PRE), and MSP Recovery (LIFW) saw their stocks rise, with Bionomics leading the gainers with a 32.7% increase. On the other hand, NovoCure (NVCR), Longeveron Inc. - Subscription Right (LGVNR), Opthea (OPT), Aditxt (ADTX), SAB Biotherapeutics (SABS), and Novo Integrated Sciences (NVOS) experienced a decrease in their stock prices, with NovoCure leading the losers with a 35.1% decrease.

Portfolio Pulse from Benzinga Insights

August 28, 2023 | 5:31 pm

During Monday's pre-market session, several health care stocks experienced significant movement. Bionomics, Geovax Labs, Tivic Health Systems, Outlook Therapeutics, Comera Life Sciences, and Societal CDMO saw increases in their stock prices, while NovoCure, Longeveron Inc. - Subscription Right, Myomo, Scilex Holding, Aptorum Gr, and Evaxion Biotech experienced decreases.

Portfolio Pulse from Benzinga Insights

August 28, 2023 | 1:06 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.